TANIA L RIVERA
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology ESCONDIDO, CA NPI 1336346972
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology CA Amgen Inc. All categories
General Payments — all program years on this page
$90,539.72
- Category: General Payments
- Program years: PY2018–2024
- Record count: 634
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $11,098.08 across 104 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,905.00 | 4 |
| Food and Beverage | $2,369.08 | 98 |
| Consulting Fee | $1,725.00 | 1 |
| Education | $99.00 | 1 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $4,880.38 | 24 |
| Acerta Pharma LLC | $2,635.88 | 6 |
| Kyowa Kirin, Inc. | $1,960.00 | 6 |
| Janssen Biotech, Inc. | $415.62 | 19 |
| UCB, Inc. | $313.00 | 12 |
| ABBVIE INC. | $265.65 | 12 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $118.06 | 4 |
| GlaxoSmithKline, LLC. | $112.50 | 4 |
| Lilly USA, LLC | $84.54 | 4 |
| Alexion Pharmaceuticals, Inc. | $72.02 | 3 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $64.27 | 2 |
| Genentech USA, Inc. | $34.62 | 2 |
| GENZYME CORPORATION | $34.11 | 1 |
| Fresenius Kabi USA, LLC | $26.22 | 1 |
| ANI Pharmaceuticals, Inc. | $22.43 | 1 |
| Aurinia Pharma U.S., Inc. | $21.37 | 1 |
| Celltrion USA Inc. | $19.70 | 1 |
| PFIZER INC. | $17.71 | 1 |
By program year
Records — PY2024 (104)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.